Intrathecal baclofen for dystonia: Benefits and complications during six years of experience

Ruth H. Walker, Fabio O. Danisi, David M. Swope, Robert R. Goodman, Isabelle M. Germano, Mitchell F. Brin

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

Fourteen patients with primary or secondary dystonia received intrathecal baclofen (ITB) through an implanted pump following a trial dose. Patients were selected for ITB trial if they had clinically unsatisfactory responses to oral antidystonic medications, including oral baclofen. Patients were rated using the Burke-Fahn-Marsden rating scale by a blinded rater after the dose of ITB was optimized. Five patients experienced improvement in symptoms as determined by a change in rating scale scores, although only two had a clear clinical benefit. Etiology of dystonia did not determine the efficacy of ITB therapy, as benefit or failure was seen in both primary and secondary dystonia.

Original languageEnglish
Pages (from-to)1242-1247
Number of pages6
JournalMovement Disorders
Volume15
Issue number6
DOIs
StatePublished - 2000

Keywords

  • Dystonia
  • Intrathecal baclofen

Fingerprint

Dive into the research topics of 'Intrathecal baclofen for dystonia: Benefits and complications during six years of experience'. Together they form a unique fingerprint.

Cite this